Icosavax
Public CompanyIcosavax develops virus-like particle vaccines targeting respiratory viruses such as RSV, hMPV, and COVID-19. Its platform uses computational protein design and virus-like particle scaffolds to create experimental vaccines intended to be shelf-stable and advance to clinical trials.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology, Vaccines, Life Sciences
- Status
- Public Company
- Stage
- Public
- Members see funding amounts. .
Is this your organization? Claim it
Members see Icosavax's funding rounds, amounts and investors.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
Neil King Co-founder